Lane 1: Hela
Lane 2: HepG2
Lane 3: A431
Lane 4: MCF-7
Lane 5: A549
Lane 6: Jurkat
Lane 7: Human kidney
Lane 8: Human brain
Lane 9: Human liver
Mouse monoclonal primary
Isocitrate dehydrogenase/IDH1 Monoclonal Antibody (EM40705)
MCF-7, HepG2, Hela, A549, A431, Jurkat, human brain tissue, human liver tissue , human kidney tissue,human colon carcinoma tissue,human breast tissue.
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A purified.
Cytosolic NADP isocitrate dehydrogenase antibody; Cytosolic NADP-isocitrate dehydrogenase antibody; Epididymis luminal protein 216 antibody; Epididymis secretory protein Li 26 antibody; HEL-216 antibody; HEL-S-26 antibody; ICDH antibody; IDCD antibody; IDH antibody; IDH1 antibody; IDHC_HUMAN antibody; IDP antibody; IDPC antibody; Isocitrate dehydrogenase [NADP] cytoplasmic antibody; Isocitrate dehydrogenase 1 (NADP+) soluble antibody; NADP dependent isocitrate dehydrogenase cytosolic antibody; NADP dependent isocitrate dehydrogenase peroxisomal antibody; NADP(+)-specific ICDH antibody; Oxalosuccinate decarboxylase antibody; PICD antibody
Belongs to the isocitrate and isopropylmalate dehydrogenases family.
Acetylation at Lys-374 dramatically reduces catalytic activity.
Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome. Mutations in IDH1 are also implicated in cancer. Originally mutations in IDH1 were detected in an integrated genomic analysis of human glioblastoma multiforme. In addition to being mutated in diffuse gliomas, IDH1 has also been shown to harbor mutations in human acute myeloid leukemia (AML).